Sensus Healthcare, Inc. (NASDAQ:SRTS) Files An 8-K Reports Third Quarter 2016 Results

Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today reported its financial results for the three and nine month periods ended September 30, 2016.

Story continues below

Recent Business Highlights

· Sold 11 systems during the quarter, increasing worldwide installed base to 256 units as of September 30, 2016
· Sold 5 SRT-100 Vision™ systems during the quarter to hospitals and dermatology practices
· Expanded keloid treatment program as over 60 facilities in the U.S. are now treating with SRT
· Featured speaker at the State of Colorado Cancer Caucus meeting comprised of state senators and representatives, along with several patient advocacy groups and local physicians

“I am pleased to report another quarter of positive results for Sensus Healthcare, as our SRT technology continues to gain favorable exposure and strong acceptance by doctors and hospitals. We have also experienced an uptick in patient awareness, as evidenced by a significant increase in direct requests to learn more about the technology and how to access treatment using our solution,” said Joseph Sardano, President and CEO of Sensus Healthcare. “For the third quarter of 2016, revenue increased year-over-year by 58 percent, from $2.1 million to $3.3 million, net loss decreased from $78,000 to $30,000 and adjusted EBITDA increased from $16,000 to $168,000, compared to the same period last year.”

Mr. Sardano continued, “With our SRT technology, we are successfully addressing two of the largest and fastest-growing segments in the skin disease market; non-melanoma skin cancer and keloids. While a majority of current use cases are for the treatment of non-melanoma skin cancer, we are seeing a significant and growing number of physicians utilizing SRT technology to treat keloids.”

Q3 2016 Financial Highlights

Revenues for Q3 2016 increased 58% to $3.33 million, compared to $2.11 million for Q3 2015.

Gross Margin for Q3 2016 was 67.6%, compared to 67.2% for Q3 2015.

Selling and Marketing Expenses for Q3 2016 were $1.12 million, compared to $0.75 million in Q3 2015. This increase was the result of increased headcount as well as expenses related to participating in trade shows.

General and Administrative Expenses for Q3 2016 were $0.79 million, compared to $0.38 million in Q3 2015. This increase was primarily due to expenses attributable to becoming a public company.

Research and Development Expenses for Q3 2016 were $0.39 million, compared to $0.36 million in Q3 2015.

GAAP Net Loss Attributable to Common Stockholders for Q3 2016 was ($0.03) million, or ($0.00) per share, compared to a net loss attributable to common stockholders of ($0.21) million, or ($0.02) per share for Q3 2015.  The net loss attributable to common stockholders for the quarter ended September 30, 2015 included a non-cash accounting charge of approximately $0.13 million for a preferential distribution attributable to preferred shareholders prior to the IPO.

Adjusted EBITDA for Q3 2016 was $0.17 million, compared to $0.02 million for Q3 2015. Adjusted EBITDA is defined as earnings before depreciation and amortization, taxes, interest expense, stock compensation expense and litigation settlement expense. Please see below for a reconciliation between GAAP and this non-GAAP financial measure and the specific reasons why we provide these non-GAAP financial measures.

Cash, Cash Equivalents and Investments were $11.2 million as of September 30, 2016.

Nine Month 2016 Financial Highlights

Revenues for the nine months ended September 30, 2016 increased 54% to $9.93 million, compared to $6.43 million for same period in 2015.

Gross Margin for the nine months ended September 30, 2016 was 65.5%, compared to a gross margin of 64.8% for the same period in 2015.

Selling and Marketing Expenses for the nine months ended September 30, 2016 were $3.24 million, compared to $2.60 million for the same period in 2015. This increase was the result of increased headcount as well as expenses related to participations in trade shows.

General and Administrative Expenses for the nine months ended September 30, 2016 were $2.55 million, compared to $1.08 million for the same period in 2015. This increase was primarily due to stock compensation expense and other expenses attributable to becoming a public company.

Research and Development Expenses for the nine months ended September 30, 2016 were $1.10 million, compared to $1.13 million for the same period in 2015.

GAAP Net Loss Attributable to Common Stockholders for the nine months ended September 30, 2016 was ($0.38) million, or ($0.03) per share, compared to a net loss attributable to common stockholders of ($1.04) million, or ($0.10) per share for the same period in 2015. The net loss attributable to common stockholders for the nine months ended September 30, 2015 included a non-cash accounting charge of approximately $0.39 million for a preferential distribution attributable to preferred shareholders prior to the IPO.

Adjusted EBITDA for the nine months ended September 30, 2016 was $0.63 million, compared to adjusted EBITDA of ($0.38) million for the same period in 2015. Adjusted EBITDA is defined as earnings before depreciation and amortization, taxes, interest expense, stock compensation expense and litigation settlement expense. Please see below for a reconciliation between GAAP and this non-GAAP financial measure and the specific reasons why we provide these non-GAAP financial measures.

Conference Call and Webcast Information

Sensus Healthcare’s third quarter 2016 conference call and webcast will be held at 4:30 pm Eastern Time on Thursday, November 3, 2016 and will feature remarks by Joseph Sardano, President and CEO, and Arthur Levine, CFO.

The dial-in numbers for the conference call are 1-877-870-4263 (Toll Free) and 1-412-317-0790 (International). Ask the operator to join you into the Sensus Healthcare Call.

A live webcast of the conference call will be available online which can be accessed through the Investor Relations section of Sensus Healthcare’s website, http://investors.sensushealthcare.com/events-and-presentations.  Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

For interested individuals unable to join the conference call, a replay of the webcast will remain available on http://investors.sensushealthcare.com/events-and-presentations for 30 days following the call.

About Sensus

Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.

 

An ad to help with our costs